Nader Francois
SEC-identified person · CIK 1365343 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Moderna, Inc. MRNA | Director | filed 2019–2026 |
| Tectonic Therapeutic, Inc. TECX | Director | filed 2026–2026 |
| Tourmaline Bio, Inc. TRML | Director | filed 2021–2023 |
| Acceleron Pharma INC XLRN | Director | filed 2014–2021 |
| Alexion Pharmaceuticals, INC. alxn | Director | filed 2017–2021 |
| Prevail Therapeutics Inc. PRVL | Director | filed 2019–2021 |
| Baxalta Inc BXLT | Director | filed 2015–2016 |
| Trevena INC TRVN | Director | filed 2014–2015 |
| NPS Pharmaceuticals INC NSPS | Director · SVP & COO | filed 2006–2015 |
| Noven Pharmaceuticals INC NOWN | Director | filed 2009–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.